

## Case report: respiratory failure – Don't Forget Myasthenia!

### Relato de caso: Falência respiratória – Não se esqueça da miastenia gravis!

Talyta Cortez Grippe<sup>1,2</sup>

Ana Carolina da Bouza Ferreira<sup>2</sup>

Ana Carolina Aguilar<sup>1</sup>

André Gustavo Fonseca Ferreira<sup>1</sup>

Manoel Wilkley Gomes Sousa<sup>1</sup>

Ronaldo Maciel Dias<sup>1</sup>

Rubens Nelson Morato Fernandez<sup>1</sup>

Elza Dias Tosta<sup>3</sup>

<sup>1</sup>Unidade de Neurologia e Neurofisiologia - Hospital de Base do Distrito Federal, Brasília – Brazil

<sup>2</sup>Faculdade de Medicina – Centro Educacional de Brasília – Brazil

<sup>3</sup>Academia Brasileira de Neurologia (ABN) - Brazil

Recebido em: 21/09/2020

Aceito em: 28/09/2020

Disponível em: 08/12/2020

Autor correspondente:

Talyta Grippe

[talytagrippe@gmail.com](mailto:talytagrippe@gmail.com)

#### ABSTRACT

Myasthenia gravis (MG) is a rare autoimmune disease in which antibodies bind to acetylcholine receptors in the postsynaptic membrane at the neuromuscular junction. Muscle-specific kinase (MuSK) antibody-associated MG patients often have severe symptoms, including bulbar dysfunction, respiratory insufficiency, and atrophy of the facial and tongue muscles. Due to its fluctuating nature and the similarity to the symptoms other disorders MG is one of the most challenging medical diagnoses. Fluctuating character and the similarity of symptoms to those of other disorders make MG one of the most challenging medical diagnoses. Initial misdiagnosis of MuSK-MG can lead to worsening of symptoms. The diagnosis is confirmed by positive results on pharmacological testing, electrodiagnostic testing and serum antibody assay. Symptomatic, immunoactive, and supportive approaches to therapy have very good effect and the prognosis is improved with precocious interventions.

**Keywords:** Myasthenia gravis. Autoantibodies. Respiratory insufficiency.

#### RESUMO

AMiasteniaGravis(MG)éumadoençaautoimune rara na qual os anticorpos se ligam aos receptores de acetilcolina na membrana pós-sináptica da junção neuromuscular. Pacientes com MG associado ao anticorpo músculo quinase específico (MuSK) frequentemente apresentam sintomas graves, incluindo disfunção bulbar, insuficiência respiratória e atrofia dos músculos faciais e da língua. O caráter flutuante e a semelhança dos sintomas com os de outras doenças tornam a MG um dos diagnósticos médicos mais desafiadores. O diagnóstico incorreto de MuSK-MG pode levar ao agravamento dos sintomas. O diagnóstico é confirmado por resultados positivos em testes farmacológicos, testes de eletrodiagnóstico e análise de anticorpos séricos. As abordagens sintomáticas, imunoativas e terapias de suporte têm um efeito positivo na sintomatologia e o prognóstico é melhorado com intervenções precoces.

**Palavras-chave:** Miastenia gravis. Autoanticorpos. Insuficiência respiratória.

## INTRODUCTION

Myasthenia gravis (MG) is an autoimmune disorder in which muscle weakness occurs because of impairment of neuromuscular transmission (CARR et al, 2010). The knowledge on myasthenia gravis pathogenesis has greatly increased, and it is now recognized to have wide clinical phenotypes based on the presence of the different autoantibodies<sup>1</sup>. MG is caused by autoantibodies that target the postsynaptic membranes of neuromuscular junctions (NMJs), cholinergic synapses that connect nerve terminals and skeletal muscle fibers<sup>2</sup>.

In Brazil, the incidence of MG varies from 1 to 9 per million inhabitants<sup>3</sup>. Symptoms are characterized by fluctuating weakness that improves with rest and worsens with exercise, infections, menstruation, anxiety, emotional stress, and pregnancy. Weakness can be limited to specific muscle groups (ocular, facial, bulbar muscles) or be generalized<sup>4</sup>.

These antibodies can be divided in three different classes: antibodies against acetylcholine receptors (AChR), muscle-specific kinase (MuSK) and lipoprotein receptor-related protein 4 (LRP4) (GILHUS, 2016). The majority of abs positive myasthenic patients have AChR antibodies, with an initial ocular symptomatology converging to a generalized form within one year and good responses to acetylcholinesterase inhibitors (AChE-I)<sup>1</sup>. Approximately 5-8% of the total number of patients with myasthenia gravis (MG) has antibodies against the muscle specific tyrosine kinase (MuSK) receptor. These patients exhibit a distinct clinical phenotype and may differ from "typical" MG associated with antibodies against the acetylcholine receptor (AChR)<sup>5</sup>. MG associated with MuSK antibodies has some distinct clinical features, including prevalent involvement of cranial and bulbar muscles and frequent intolerance of (AChE-I). Cramps and fasciculations may also occur in patients with MG following treatment with AChE-I, particularly in patients with MuSK-MG<sup>6</sup>.

MG remains one of the most challenging medical diagnoses due to its fluctuating character and to the similarity of its symptoms to those of other disorders<sup>7</sup>. The initial clinical course might be interpreted as fatigue, tiredness, or laziness. So,

the complication with respiratory insufficiency may lack a previous clinical history that would help with the diagnosis. We would like to present a case that exemplify these "false" acute presentation for myasthenia.

## METHODS

Medical Reports review.

## CASE REPORT

A 45-year-old woman went to the general physician complaining of dyspnea, she was no longer able to perform her dance classes. She had an unremarkable spirometry and showed night desaturation in the polysomnography. She started domiciliary oxygen at night and was referred to a pneumologist.

Before the consultation, she had an acute episode of ventilatory insufficiency associated with a decrease in consciousness level (gasometer analysis: SpO<sub>2</sub>: 92%, PCO<sub>2</sub>: 90mmHg, PaO<sub>2</sub>: 72.2 mmHg). She went to the emergency room and was submitted to mechanical ventilation. Pulmonary thromboembolism was ruled out after angiotomography. The tomography revealed a pneumonic infiltration, she was treated with antibiotics. A bronchospasm therapy with the use of venous hydrocortisone was added after the evidence of wheezing on auscultation. She got better after the whole treatment without oxygen dependence and went back home. The medical team listened to her family that reported she was feeling weak for about one year and was also sadder since her husband was diagnosed with cancer, always with an unhappy face. So, it was suggested that her respiratory failure was secondary to a psychogenic disorder and she was referred to the psychiatry. Two weeks later, she started to feel the same symptoms again, and needed to use night oxygen.

She has referred to our team at the occasion. The first examination showed a restricted gaze upwards and restricted adduction on the bilateral gaze with a bilateral ptosis with no fluctuation during the day. The palate elevation and nausea

reflex were impaired, with an inefficient swallow. Global force, sensibility, coordination, and tendon reflexes were preserved. The gasometer showed high CO<sub>2</sub> pressure (60 – 70 mmHg), her spirometry showed a restrictive and obstructive pattern and the manovacuometry was normal. The electromyography showed no alterations even after the repetitive stimulation. The ice test was negative, the pyridostigmine test showed a slightly improvement of the upward gaze and lateral gaze. The laboratory exams revealed normal thyroid, liver and kidney function, normal creatine phosphokinase (cpk)(91 U/L) and lactate (0,2 – 2,4 mg/dL) value. We ordered the anti-acetylcholine dosage and decided to use the pyridostigmine for a myasthenia therapeutic test.

On the next day, she presented a tongue fasciculation. There was no improvement with pyridostigmine, and the anti-acetylcholine was negative. The ventilatory function was getting worse. Therefore, we decided to ask for an anti-musk dosage and tried an empirical treatment with immunoglobulin (there were no availability of plasmapheresis – our first option). After, 2g/kg of immunoglobulin she presented no improvement.

The dosage of anti-musk was positive, and we started prednisone – 1mg/Kg. She continued with BIPAP, showed an initial decline in the ventilatory function followed by an improvement. Nowadays she is using azathioprine, gradually tapping the prednisone and need no more oxygen supplementation.

## DISCUSSION

In this report, we described a case of a patient with myasthenia gravis MuSK positive with missed signs of her clinical presentation and a misdiagnosis. Some important clinical aspects regarding her case will be discussed in order to focus the relevant signs and symptoms to guide a diagnosis of myasthenia.

The clinical presentation of MuSK-MG patients can be atypical and symptom fluctuation, which is a clinical hallmark of MG, can be minimal or absent<sup>8</sup>. Respiratory muscle weakness can occur in up to 40% of MG patients leading to dyspnea or orthopnea. Roughly 15% to 20% of patients

with MG will experience myasthenic crisis, defined as respiratory failure necessitating either noninvasive positive pressure ventilation or mechanical ventilation until clinical improvement occurs. Respiratory muscle weakness is typically associated with concurrent bulbar and neck muscle weakness and more predominant in MuSK + patients<sup>2,8,9</sup>, as showed by our patient.

Patients with both defined and undiagnosed neuromuscular disorders are frequently admitted to hospital services and clinicians must be able to recognize and intervene appropriately when respiratory failure develops. Early recognition of acute neuromuscular respiratory failure (NRF) and determination of the cause is imperative, as there are survival implications<sup>10</sup>.

In general, failure of the lung caused by a variety of lung diseases (e.g. pneumonia, emphysema, and interstitial lung disease) leads to hypoxaemia with normocapnia or hypocapnia (hypoxaemic or type I respiratory failure). Failure of the pump (e.g. drug overdose) results in alveolar hypoventilation and hypercapnia (hypercapnic or type II respiratory failure). Although there is coexistent hypoxaemia, the hallmark of ventilatory failure is the increase in PCO<sub>2</sub><sup>11</sup>.

When the diaphragm and intercostal muscles become sufficiently weak that they cannot lift the ribcage, accessory muscles attached to the ribcage are enlisted to move it and assist with ventilation. These compensatory mechanisms provide only partial compensation, resulting in microatelectasis at the lung bases. At this stage, the patient may be tachypneic and examination of the arterial blood gas (ABG) will show a respiratory alkalosis with normal or mildly reduced PO<sub>2</sub>. As the muscles fatigue, generalized hypoventilation develops. The patient compensates by increasing their respiratory rate further (rapid shallow breathing) and thus testing of the blood gas at this stage will reveal a normal PCO<sub>2</sub>. Further muscular fatigue leads eventually to hypercapnia and respiratory acidosis<sup>10</sup>. Mechanical defects of the chest wall (flail chest and acute hyperinflation), neuromuscular diseases (bilateral diaphragmatic paralysis, myasthenia Gravis, botulism and Guillain-Barre' syndrome) and pharmacological agents such as curare may result in acute hypercapnia<sup>11</sup>.

A diurnal fluctuation of myasthenic symptoms may not be evident in some patients. The often negative edrophonium test and/or negative repetitive nerve stimulation study may make the MuSK-MG diagnosis less obvious. It is important to differentiate MuSK-MG from amyotrophic lateral sclerosis (ALS), since both can present tongue atrophy and fasciculation as reported in the case. In MuSK-MG upper motor neuron dysfunction is usually absent, creatine kinase level is typically normal, and the denervation is rarely seen on needle electromyography<sup>12</sup>.

Moreover, it is important to emphasize the possible co-existence of myasthenia and depression, that is present in our case. Since the fatigability present in myasthenic patients can resemble a sad face or apathy, it is always important to evaluate if the depression really explain all the symptoms of the patient.

For cost effectiveness, MuSK-Ab testing should be reserved for patients who have tested seronegative for AChR-Abs or patients who have tested positive for AChR-Ab but respond poorly to treatment<sup>12</sup>. Therefore, only the anti-acetylcholine dosage was ordered initially and the MuSK dosage was reserved in case there was a poor response to the conventional treatment.

Therapeutic management of MG is based on the use, most often in combination, of acetylcholinesterase inhibitors (AChE-I) as symptomatic medication, thymectomy, pharmacological immunosuppression, and short-term immunomodulation with plasma-exchange and intravenous immunoglobulin (IVIg). Pyridostigmine is the AChE-I agent most commonly used, it is generally well tolerated and represents the first-line treatment in MG,<sup>13</sup>. Thymectomy is indicated to all patients with thymoma to treat a potentially malignant tumor; moreover, it is currently performed in generalized AChR-MG, it appears to increase the likelihood of medication-free remission and reduce the patients hospitalization<sup>14,15</sup>. Several lines of evidence suggest that thymectomy may not be beneficial for MuSK-MG. The MuSK-Ab level remains unchanged after thymectomy in contrast to its reduction after successful immunosuppression. Histological findings of the thymus gland removed from patients with MuSK-MG were often normal

for age or atrophic<sup>6</sup>. Thymus alteration appears to be definitely uncommon in MuSK-MG, supporting the view that the thymus does not play a pathogenic role in this form of MG<sup>8</sup>.

Immunosuppressive treatment reduces the level of pathogenic antibodies through different effects on immune system and is performed in patients with disabling symptoms, not satisfactorily controlled with AChE-Is. It includes corticosteroids, alone or in combination with a variety of drugs as antimetabolites (azathioprine, mycophenolate mofetil), calcineurin inhibitors (cyclosporine, tacrolimus), alkylating agents (cyclophosphamide) and rituximab<sup>16</sup>. Plasmaexchange removes antibodies and cytokines from circulation, while IVIg has complex effects on the immune system mostly mediated through interference with idiotype network and modulation of T and B cell activation. Both plasma-exchange and IVIg induce rapid, though short-term improvement, and are mainly employed in association with pharmacological immunosuppression, in treating disease exacerbation phases and in preparation for thymectomy<sup>8</sup>.

Regarding our case, the next day after starting the pyridostigmine the patient showed no improvement and presented a tongue fasciculation together with ventilatory function deterioration. In MuSK-MG animal models, clinically appropriate doses of pyridostigmine exacerbated weakness, end plate AChR loss and impaired end plate electrophysiological measures in the diaphragm muscle. Hypersensitivity to ACEI merits extra caution when treating patients with MuSK-MG who are at risk for myasthenic crisis because increased bronchial and oropharyngeal secretions could further aggravate impaired breathing and/or swallowing<sup>12</sup>.

Immunosuppression is the mainstay treatment in all forms of MG. This is particularly true in MuSK-MG, where weakness severity and poor response to AChE-Is imply prompt and aggressive treatment<sup>17</sup>. Currently, the 3 most effective treatments for MuSK MG are corticosteroids, plasmapheresis, and rituximab<sup>12</sup>. There is a general agreement that MuSK-MG responds well to steroids and dramatically to plasma-exchange. The association of high-dose prednisone (1 to 1.5 mg/kg body weight/day) and plasma-exchange (five exchanges of 40 to 50 ml/body weight each

on alternate days) is the treatment of choice in patients with respiratory crisis or severe bulbar weakness, as in other forms of MG<sup>8</sup>.

However, after the positive dosage of anti-MuSK-Ab the patient showed no improvement with the use of immunoglobulin and we had to start the prednisone. Her ventilatory function has improved and the oxygen supplementation is no longer needed. Response to corticosteroids is relatively fast, usually within 2–3 weeks. Because of the rapid onset of action, corticosteroids are often the firstline immunotherapy for MuSK-MG. However, the maintenance of corticosteroid dose may be higher in MuSK-MG compared with that used for AChR- MG<sup>12</sup>.

## CONCLUSION

The early diagnosis of acute neuromuscular respiratory failure and the determination of the cause are extremely relevant because they can interfere on the patients' survival and comorbidities. Neuro-muscular diseases should be always investigated in type II respiratory failure, considering that the determination of the cause required strenuous investigation, alternated with empirical attempts at treatment, demonstrating the importance of recognizing the possible differential diagnoses for controlling the disease course.

Myasthenia gravis remains a challenging diagnosis for doctors, since it has different spectra of clinical manifestations, in addition to a fluctuating course and characteristics similar to other diseases, which makes it even more relevant to raise it as a diagnostic hypothesis by attending physicians.

## CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

## REFERÊNCIAS BIBLIOGRÁFICAS

1. Mantegazza R, Bernasconi P, Cavalcante P. Myasthenia gravis: from autoantibodies to therapy. *Curr Opin Neurol* 2018;31:517–25. doi:10.1097/WCO.0000000000000596.

2. Mori S, Shigemoto K. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. *Autoimmun Rev* 2013;12:912–7. doi:10.1016/j.autrev.2013.03.005.

3. Brasil. Ministério da Saúde. Portaria no 1.169, de 19 de novembro de 2015. vol. 222. 2015. <https://www.in.gov.br/web/dou/-/portaria-n-1-169-de-19-de-novembro-de-2015-33335188>. (accessed September 16, 2020).

4. Gilhus NE. Myasthenia Gravis. *N Engl J Med* 2016;375:2570–81. doi:10.1056/NEJMra1602678.

5. Furuta N, Ishizawa K, Shibata M, Tsukagoshi S, Nagamine S, Makioka K, et al. Anti-MuSK Antibody-positive Myasthenia Gravis Mimicking Amyotrophic Lateral Sclerosis. *Intern Med* 2015;54:2497–501. doi:10.2169/internalmedicine.54.4645.

6. Simon NG, Reddel SW, Kiernan MC, Layzer R. Muscle-specific kinase antibodies: A novel cause of peripheral nerve hyperexcitability?: MuSK Antibodies in PNH. *Muscle Nerve* 2013;48:819–23. doi:10.1002/mus.23907.

7. Juel VC, Massey JM. Myasthenia gravis. *Orphanet J Rare Dis* 2007;2:44. doi:10.1186/1750-1172-2-44.

8. Evoli A, Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. *Autoimmun Rev* 2013;12:931–5. doi:10.1016/j.autrev.2013.03.004.

9. Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis. *Neurol Clin* 2018;36:253–60. doi:10.1016/j.ncl.2018.01.002.

10. Hocker S. Primary Acute Neuromuscular Respiratory Failure. *Neurol Clin* 2017;35:707–21. doi:10.1016/j.ncl.2017.06.007.

11. Roussos C, Koutsoukou A. Respiratory failure. *Eur Respir J* 2003;22:35–14s. doi:10.1183/09031936.03.00038503.

12. Morren J, Li Y. Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review: Myasthenia Gravis With MuSK-Ab. *Muscle Nerve* 2018;58:344–58. doi:10.1002/mus.26107.

13. Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology. *Neurol Clin* 2018;36:253–60. doi:10.1016/j.ncl.2018.01.002.
14. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. *N Engl J Med* 2016;375:511–22. doi:10.1056/NEJMoa1602489.
15. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. *Lancet Neurol* 2019;18:259–68. doi:10.1016/S1474-4422(18)30392-2.
16. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology* 2016;87:419–25. doi:10.1212/WNL.0000000000002790.
17. Evoli A, Alboini PE, Bissoni A, Mastroianni A, Bartoccioni E. Management challenges in muscle-specific tyrosine kinase myasthenia gravis: Management challenges in MuSK-MG. *Ann N Y Acad Sci* 2012;1274:86–91. doi:10.1111/j.1749-6632.2012.06781.x.